Details for Patent: 10,869,870

Which drugs does patent 10,869,870 protect, and when does it expire?

Patent 10,869,870 protects OPZELURA and is included in one NDA.

Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-eight patent family members in thirty-four countries.

Summary for Patent: 10,869,870

Title:	Topical formulation for a JAK inhibitor
Abstract:	This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]- propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Inventor(s):	Parikh; Bhavnish (Avondale, PA), Shah; Bhavesh (San Antonio, TX), Yeleswaram; Krishnaswamy (Landenberg, PA)
Assignee:	Incyte Corporation (Wilmington, DE)
Application Number:	16/947,735
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 10,869,870

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y

International Family Members for US Patent 10,869,870

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	084691
Argentina	124134
Australia	2011255443